This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: Exelixis

BOSTON ( TheStreet) -- Welcome to this week's Biotech Stock Mailbag. @biotechbaumer asks, "Do you know timeframe when FDA expected to make decision on SPA for $EXEL to use bone mets as primary endpoint in CRPC?"

I'll translate that tweet: He's asking if there is a time frame for when the Food and Drug Administration and Exelixis (EXEL - Get Report) are expected to reach agreement on a special protocol assessment (SPA) nailing down the design of the first pivotal, phase III study of Exelixis' prostate cancer drug cabozantinib.

Exelixis has said publicly that it expects to begin the phase III study of cabozantinib ("cabo") before the end of the year. In order to meet that timeline, the company must reach agreement with FDA on the SPA. It's nearly November, so clearly, the SPA agreement, if one is agreed to, will be coming soon.

Thursday night, Exelixis said it expects that FDA feedback "shortly."

Exelixis is proposing a phase III study for cabo that will use a composite primary endpoint of bone lesion clearance and pain resolution. Patients enrolled in this study will have advanced, metastatic prostate cancer that no longer responds to the standard chemo regimen of Taxotere or newer drugs like Johnson & Johnson's Zytiga (JNJ - Get Report) and Sanofi's (SNY) Jevtana. These are very sick prostate cancer patients with significant prostate cancer-related pain who have few or no treatment options left.

This cabo study design is a point of controversy for investors (and an overhang on the Exelixis' stock price) because Exelixis is choosing not to use overall survival as the primary endpoint. All recently approved prostate cancer drugs -- Zytiga, Jevtana and Dendreon's Provenge -- used a survival benefit as the basis for approval. Still, experimental prostate cancer drugs from Medivation (MDVN - Get Report) and Algeta both employed overall survival in their respective phase III studies.

Exelixis believes demonstrating cabo's ability to shrink or eliminate the spread of prostate cancer to bone, which causes patients a lot of pain, is a clinically significant benefit and enough to convince FDA to approve the drug. To support their position, Exelixis points to the FDA's own guidance stating prostate cancer drugs can be approved on the basis of pain resolution. Mitoxantrone was approved for prostate cancer using a pain reduction endpoint in 1996.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CTIC $1.81 0.00%
EXEL $2.54 0.00%
JNJ $100.34 0.00%
MDVN $132.00 0.00%
NVS $100.40 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs